During the posttreatment 6‐week safety follow‐up after discontinuing rilonacept study drug (n=25 non‐US patients after study closure; n=12 US patients completing the study without transition to commercial rilonacept), 5 additional investigator‐assessed pericarditis recurrences (NRS >6; CRP >1 mg/dL; met RHAPSODY adjudication criteria) were reported, at 3 weeks (in 1 patient) and at 6 weeks (in 4 patients) (see Data S1). Here, CRP is linked to pericarditis.